Citations (42)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Dirk Schriefer, Rocco Haase, Jennifer S Kullmann & Tjalf Ziemssen. (2020) Health-Related Quality of Life and the Relationship to Treatment Satisfaction in Patients with Multiple Sclerosis: Insights from a Large Observational Study. Patient Preference and Adherence 14, pages 869-880.
Read now
Read now
Luis Lizán, Marta Comellas, Silvia Paz, José Luis Poveda, Dennis M Meletiche & Carlos Polanco. (2014) Treatment adherence and other patient-reported outcomes as cost determinants in multiple sclerosis: a review of the literature. Patient Preference and Adherence 8, pages 1653-1664.
Read now
Read now
Kristin A Hanson, Neetu Agashivala, Kathleen W Wyrwich, Karina Raimundo, Edward Kim & David W Brandes. (2014) Treatment selection and experience in multiple sclerosis: survey of neurologists. Patient Preference and Adherence 8, pages 415-422.
Read now
Read now
MerriKay Oleen-Burkey, Anissa Cyhaniuk & Eric Swallow. (2013) Treatment patterns in multiple sclerosis: administrative claims analysis over 10 years. Journal of Medical Economics 16:3, pages 397-406.
Read now
Read now
Slobodan M Jankovic. (2010) Injectable interferon beta-1b for the treatment of relapsing forms of multiple sclerosis. Journal of Inflammation Research 3, pages 25-31.
Read now
Read now
Matthew W. Reynolds, Reejis Stephen, Chris Seaman & Kitty Rajagopalan. (2010) Healthcare resource utilization following switch or discontinuation in multiple sclerosis patients on disease modifying drugs. Journal of Medical Economics 13:1, pages 90-98.
Read now
Read now
Ralf A Linker, De-Hyung Lee, Martin Stangel & Ralf Gold. (2008) Fumarates for the treatment of multiple sclerosis: potential mechanisms of action and clinical studies. Expert Review of Neurotherapeutics 8:11, pages 1683-1690.
Read now
Read now
Articles from other publishers (35)
Aliza Bitton Ben-Zacharia, Bryan Walker, Amy Perrin Ross, Carlo Tornatore, Natalie C. Edwards, Yvette Lipman & Amy L. Phillips. (2023) Factors Associated With Disease-Modifying Therapy Adherence and Persistence in Multiple Sclerosis: A Scoping Literature Review. International Journal of MS Care 25:5, pages 188-195.
Crossref
Crossref
Michael Guger, Michael Matthias Ackerl, Martin Heine, Christiane Hofinger-Renner, Heinrich Karl Spiss, Andrea Taut, Karin Unger & Fritz Leutmezer. (2022) Favorable benefit–risk ratio with teriflunomide treatment in relapsing-remitting multiple sclerosis: Results of the 2-year, multicenter, prospective, noninterventional TAURUS MS study in Austria. eNeurologicalSci 27, pages 100396.
Crossref
Crossref
Foziah Alshamrani & Hind Alnajashi. (2021) Multiple sclerosis patients and e-health system in Saudi Arabia. International Journal of Human Rights in Healthcare 15:2, pages 118-127.
Crossref
Crossref
Gesa E.A. Pust, Benthe Untiedt, Jennifer Randerath, Anna Barabasch, Sascha Köpke, Anne C. Rahn, Hilke Hansen & Christoph Heesen. (2020) Exploring Adherence to First-Line and Second-Line Immunotherapies in Multiple Sclerosis. International Journal of MS Care 22:5, pages 219-225.
Crossref
Crossref
Adel Alhazzani, Mohammed Alqahtani, Noof Alamri, Leen Sarhan, Shahad Alkhashrami & Mohammed Alahmarii. (2019) Treatment satisfaction and adherence to medications among multiple sclerosis patients in Saudi Arabia. The Egyptian Journal of Neurology, Psychiatry and Neurosurgery 55:1.
Crossref
Crossref
Ricardo Alonso, Edgar Carnero Contentti, Gaston Imhoff, Pablo A. Lopez, Adrian Rubstein & Santiago Tizio. (2019) Barriers against a successful MS treatment: The importance of effectiveness beyond efficacy. Multiple Sclerosis and Related Disorders 30, pages 129-135.
Crossref
Crossref
Emma Bartolomé-García, Ángela Usarralde-Pérez, Patricia Sanmartín-Fenollera & Monserrat Pérez-Encinas. (2019) Persistence and adherence to interferon and glatiramer acetate in patients with multiple sclerosis. European Journal of Hospital Pharmacy 26:1, pages 23-28.
Crossref
Crossref
Oscar Fernández, Eduardo Duran, Teresa Ayuso, Luis Hernández, Inmaculada Bonaventura & Mireia Forner. (2017) Treatment satisfaction with injectable disease-modifying therapies in patients with relapsing-remitting multiple sclerosis (the STICK study). PLOS ONE 12:10, pages e0185766.
Crossref
Crossref
. (2017) Ocrelizumab in Primary Progressive and Relapsing Multiple Sclerosis. New England Journal of Medicine 376:17, pages 1692-1694.
Crossref
Crossref
Gurpreet K Reen, Eli Silber & Dawn W Langdon. (2017) Multiple sclerosis patients' understanding and preferences for risks and benefits of disease-modifying drugs: A systematic review. Journal of the Neurological Sciences 375, pages 107-122.
Crossref
Crossref
Gioacchino Lavanco, Carolina Messina & Laura Clorinda Rinaldi. (2017) "Per non morire prima". Strategie di coping in donne con sclerosi multipla. PSICOLOGIA DI COMUNITA':2, pages 79-94.
Crossref
Crossref
Caroline Vieira Spessotto, Hanaie Cavalli, Audred Cristina Biondo Eboni, Rafael Berlezi Machado, Analara Munardi Mousquer, Lara Both Palazzo, Alessandro Finkelsztejn, Marcus Vinicius Magno Goncalves, Henry Koiti Sato, Fabio Siquineli & Yara Dadalti Fragoso. (2016) Patients’ satisfaction with and views about treatment with disease-modifying drugs in multiple sclerosis. Arquivos de Neuro-Psiquiatria 74:8, pages 617-620.
Crossref
Crossref
Rocco Haase, Jennifer S. Kullmann & Tjalf Ziemssen. (2016) Therapy satisfaction and adherence in patients with relapsing–remitting multiple sclerosis: the THEPA-MS survey. Therapeutic Advances in Neurological Disorders 9:4, pages 250-263.
Crossref
Crossref
Miriam Kip & Heinz Wiendl. 2016. Weißbuch Multiple Sklerose. Weißbuch Multiple Sklerose
55
93
.
Kerstin Hansen, Katrin Schüssel, Marita Kieble, Johanna Werning, Martin Schulz, Robert Friis, Dieter Pöhlau, Norbert Schmitz & Joachim Kugler. (2015) Adherence to Disease Modifying Drugs among Patients with Multiple Sclerosis in Germany: A Retrospective Cohort Study. PLOS ONE 10:7, pages e0133279.
Crossref
Crossref
A. Saiz, S. Mora & J. Blanco. (2015) Treatment compliance with first line disease-modifying therapies in patients with multiple sclerosis. COMPLIANCE Study. Neurología (English Edition) 30:4, pages 214-222.
Crossref
Crossref
A. Saiz, S. Mora & J. Blanco. (2015) Cumplimiento terapéutico con terapias modificadoras de la enfermedad de primera línea en pacientes con esclerosis múltiple. Estudio COMPLIANCE. Neurología 30:4, pages 214-222.
Crossref
Crossref
MerriKay Oleen-Burkey, Anissa Cyhaniuk & Eric Swallow. (2014) Retrospective US database analysis of persistence with glatiramer acetate vs. available disease-modifying therapies for multiple sclerosis: 2001–2010. BMC Neurology 14:1.
Crossref
Crossref
Florian Deisenhammer. (2014) Interferon-Beta: Neutralizing Antibodies, Binding Antibodies, Pharmacokinetics and Pharmacodynamics, and Clinical Outcomes. Journal of Interferon & Cytokine Research 34:12, pages 938-945.
Crossref
Crossref
Bonnie I. Glanz, Alexander Musallam, David J. Rintell, Tanuja Chitnis, Howard L. Weiner & Brian C. Healy. (2014) Treatment Satisfaction in Multiple Sclerosis. International Journal of MS Care 16:2, pages 68-75.
Crossref
Crossref
Sigbj?rn Rogne. (2014) S. Rogne svarer:. Tidsskrift for Den norske legeforening 134:23/24, pages 2240-2241.
Crossref
Crossref
N. Grytten, J. H. Aarseth, K. Espeset, G. B. Johnsen, R. Wehus, C. Lund & R. C. Haugstad. (2013) Stoppers and non-starters of disease-modifying treatment in multiple sclerosis. Acta Neurologica Scandinavica 127:2, pages 133-140.
Crossref
Crossref
Sanober Nusrat, David Levinthal & Klaus Bielefeldt. (2013) Hospitalization Rates and Discharge Status in Multiple Sclerosis. Multiple Sclerosis International 2013, pages 1-7.
Crossref
Crossref
G Giovannoni, E Southam & E Waubant. (2012) Systematic review of disease-modifying therapies to assess unmet needs in multiple sclerosis: tolerability and adherence. Multiple Sclerosis Journal 18:7, pages 932-946.
Crossref
Crossref
C. Vicente Iturbe, J.R. Ara Callizo, R. Huarte Lacunza, H. Navarro Aznárez, N. Serrano Mislata & M.J. Rabanaque Hernández. (2012) Discontinuación y adherencia a largo plazo en la terapia con interferón beta en pacientes con esclerosis múltiple. Farmacia Hospitalaria 36:2, pages 77-83.
Crossref
Crossref
M. M?urer, R. Dachsel, S. Domke, S. Ries, G. Reifschneider, A. Friedrich, P. Knorn, H. Landefeld, G. Niemczyk, P. Schicklmaier, C. Wernsd?rfer, S. Windhagen, H. Albrecht & S. Schwab. (2011) Health care situation of patients with relapsing-remitting multiple sclerosis receiving immunomodulatory therapy: a retrospective survey of more than 9000 German patients with MS. European Journal of Neurology 18:8, pages 1036-1045.
Crossref
Crossref
Florian Deisenhammer. 2011. Detection and Quantification of Antibodies to Biopharmaceuticals. Detection and Quantification of Antibodies to Biopharmaceuticals
119
131
.
Simona Malucchi, Francesca Gilli, Marzia Caldano, Arianna Sala, Marco Capobianco, Alessia Sapio, Letizia Granieri & Antonio Bertolotto. (2010) One-year evaluation of factors affecting the biological activity of interferon beta in multiple sclerosis patients. Journal of Neurology 258:5, pages 895-903.
Crossref
Crossref
Howard Zwibel, Gabriel Pardo, Shelly Smith, Douglas Denney & MerriKay Oleen-Burkey. (2010) A multicenter study of the predictors of adherence to self-injected glatiramer acetate for treatment of relapsing-remitting multiple sclerosis. Journal of Neurology 258:3, pages 402-411.
Crossref
Crossref
Loredana La Mantia, Luca M Munari & Roberta Lovati. 1996. Cochrane Database of Systematic Reviews. Cochrane Database of Systematic Reviews.
Sabine Twork & Joachim Kugler. (2009) Lebensqualität bei Multipler SkleroseQuality of life of patients with multiple sclerosis: assessment of determinants. Heilberufe 61:S1, pages 13-21.
Crossref
Crossref
Loredana La Mantia, George Ebers, Sten Fredrikson & Graziella Filippini. 1996. Cochrane Database of Systematic Reviews. Cochrane Database of Systematic Reviews.
Amy Perrin Ross. (2008) Tolerability, adherence, and patient outcomes. Neurology 71:24_suppl_3.
Crossref
Crossref
Amy Perrin Ross. (2008) Strategies for optimal disease management, adherence, and outcomes in multiple sclerosis patients. Neurology 71:24_suppl_3.
Crossref
Crossref
. (2008) Current awareness: Pharmacoepidemiology and drug safety. Pharmacoepidemiology and Drug Safety 17:5.
Crossref
Crossref